| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2015: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2014: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2013: ¥12,350,000 (Direct Cost: ¥9,500,000、Indirect Cost: ¥2,850,000)
|
|---|
| Outline of Final Research Achievements |
In vivo safety and efficacy of artificial red cells (Hb-vesicles, Hb-V) as a transfusion alternative have been clarified extensively. Gradual autoxidation of ferrous Hb in Hb-V to form ferric metHb is inevitable and results in decreased oxygen carrying capacity. We found that metHb in Hb-V can be reduced to ferrous Hb by using the electron energies produced by erythrocyte glycolysis, via methylene blue as a transmembrane electron mediator. We tested other 14 candidate mediators, and found some other potential molecules that can reduce metHb effectively, as did methylene blue. The requisite chemical properties as a potential electron mediator are clarified. We established an indirect enzymatic metHb reducing system for Hb-V using unlimited endogenous electrons created in RBCs in combination with an effective electron mediator that prolongs the functional lifespan of HbV in blood circulation.
|
